CDK9 Inhibitor Design via Local Quality and Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions regulated by serine kinase activity, such as cancer, lack effective cyclin-dependent kinase CDK9 inhibitors that can specifically target and inhibit CDK9 activity without causing adverse effects on normal cellular processes.
Innovation Solution
Development of specific compounds, including those of formula (I), which act as CDK9 inhibitors, comprising p-fluorobenzoyl, trans-4-aminocyclohexyl, and their derivatives, that can selectively inhibit CDK9 kinase activity, thereby regulating cell cycle and transcription processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cancer and other conditions regulated by serine kinase activity are used, then general serine kinase inhibition is achieved, but specificity for CDK9 is lost leading to adverse effects on normal cellular processes
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (p-fluorobenzoyl group at position 2, trans-4-aminocyclohexyl group at position 4 of the pyridine ring) that provide selective binding to CDK9's unique active site architecture. This localized structural optimization enables specific inhibition of CDK9 while sparing other serine kinases, thereby achieving reliable CDK9-specific inhibition without broad-spectrum adverse effects on normal cellular processes.
2Productivity
If CDK9 activity is inhibited to reduce tumor growth and cancer cell proliferation, then therapeutic efficacy is improved, but potential off-target effects on other cellular functions may occur
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters including the fluorine substituent position on the benzoyl group, the stereochemistry of the cyclohexyl ring (trans configuration), and the positioning of amino groups to optimize binding affinity and selectivity for CDK9. These parameter optimizations enhance therapeutic efficacy through potent CDK9 inhibition while maintaining selectivity that prevents off-target effects on other cellular functions.
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
The present invention relates to an inhibitor of cyclin-dependent kinase CDK9, having a structure of formula (I). The present invention also provides a method of treating a cancer of a precancerous condition related to CDK9 activity with the inhibitor and a use of the same.